Vertex Pharms Drug Patent Portfolio
Vertex Pharms owns 2 orange book drugs protected by 12 US patents Given below is the list of Vertex Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10646481 | Pharmaceutical composition and administrations thereof | 13 Aug, 2029 | Active |
| US11564916 | Pharmaceutical composition and administrations thereof | 13 Aug, 2029 | Active |
| US8431615 | Dose forms | 30 May, 2028 | Active |
| US8324242 | Modulators of ATP-binding cassette transporters | 05 Aug, 2027 | Active |
| US7495103 | Modulators of ATP-binding cassette transporters | 20 May, 2027 | Active |
| US8410274 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | 28 Dec, 2026 | Active |
| US8754224 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | 28 Dec, 2026 | Active |
| US9670163 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | 28 Dec, 2026 | Active |
| US8354427 | Modulators of ATP-binding cassette transporters | 06 Jul, 2026 | Active |
| US8629162 | Modulators of ATP-binding cassette transporters | 24 Jun, 2025 | Active |
| US7820671 | Peptidomimetic protease inhibitors | 25 Feb, 2025 | Active |
| US8529882 | Peptidomimetic protease inhibitors | 31 Aug, 2021 | Expired |
Latest Legal Activities on Vertex Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Vertex Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Jul, 2024 | US8354427 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 04 Jun, 2024 | US8324242 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Nov, 2023 | US10646481 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Sep, 2023 | US11752106 |
| Mail Patent eGrant Notification | 12 Sep, 2023 | US11752106 |
|
Email Notification
Critical
| 12 Sep, 2023 | US11752106 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Sep, 2023 | US11752106 |
| Patent eGrant Notification | 12 Sep, 2023 | US11752106 |
| Recordation of Patent eGrant | 12 Sep, 2023 | US11752106 |
|
Email Notification
Critical
| 24 Aug, 2023 | US11752106 |
|
Issue Notification Mailed
Critical
| 23 Aug, 2023 | US11752106 |
| Dispatch to FDC | 04 Aug, 2023 | US11752106 |
|
Application Is Considered Ready for Issue
Critical
| 04 Aug, 2023 | US11752106 |
|
Issue Fee Payment Received
Critical
| 20 Jul, 2023 | US11752106 |
|
Issue Fee Payment Verified
Critical
| 20 Jul, 2023 | US11752106 |
Vertex Pharms Drug Patents' Oppositions Filed in EPO
Vertex Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 03, 2017, by Georg Kalhammer/Stephan Teipel. This opposition was filed on patent number EP06848237A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17204189A | Sep, 2021 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP17204189A | Sep, 2021 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
| EP17204189A | Sep, 2021 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP10708442A | Oct, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP06848237A | Nov, 2017 | Georg Kalhammer/Stephan Teipel | Opposition rejected |
Vertex Pharms's Family Patents
Vertex Pharms Drug List
Given below is the complete list of Vertex Pharms's drugs and the patents protecting them.
1. Incivek
Incivek is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8431615 | Dose forms |
30 May, 2028
(3 years from now)
| Active |
| US7820671 | Peptidomimetic protease inhibitors |
25 Feb, 2025
(4 months from now)
| Active |
| US8529882 | Peptidomimetic protease inhibitors |
31 Aug, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Incivek's drug page
2. Kalydeco
Kalydeco is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10646481 | Pharmaceutical composition and administrations thereof |
13 Aug, 2029
(4 years from now)
| Active |
| US11564916 | Pharmaceutical composition and administrations thereof |
13 Aug, 2029
(4 years from now)
| Active |
| US8324242 | Modulators of ATP-binding cassette transporters |
05 Aug, 2027
(2 years from now)
| Active |
| US7495103 | Modulators of ATP-binding cassette transporters |
20 May, 2027
(2 years from now)
| Active |
| US8410274 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
| US8754224 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
| US9670163 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
28 Dec, 2026
(2 years from now)
| Active |
| US8354427 | Modulators of ATP-binding cassette transporters |
06 Jul, 2026
(1 year, 8 months from now)
| Active |
| US8629162 | Modulators of ATP-binding cassette transporters |
24 Jun, 2025
(8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kalydeco's drug page